Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 601–700 of 1,001
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
Park, B. J., Lee, A., Ye, F., Turker, I., & Johnson, D. B. (2022) · BMC Cancer · doi:10.1186/s12885-022-10090-9 · Cited by 7
“Although largely reversible, progression of steatosis may result in steatohepatitis and further progression to fibrosis, cirrhosis, and hepatocellular carcinoma [12].”
BackgroundMeyer, E. L., Mesenbrink, P. G., Prospero, N. A. D., Pericàs, J. M., Glimm, E., Ratziu, V., Sena, E., König, F., & on behalf of the EU-PEARL NASH Investigators (2023) · PLoS ONE · doi:10.1371/journal.pone.0281674 · Cited by 7
“So when simulating phase 3 designs for NASH it should also incorporate the cumulative incidence of important clinical outcomes [38, 39] as the baseline risk and include clinically relevant outcomes such as prevention of cirrhosis.”
Abeysekera, K. W. M., Srivastava, A., Rowe, I. A. C., Jarvis, H., Ryder, S. D., Yeoman, A. D., Dillon, J. F., & Rosenberg, W. M. (2023) · Frontline Gastroenterology · doi:10.1136/flgastro-2023-102415 · Cited by 9
Huang, J., Tsai, P., Yeh, M., Huang, C., Huang, C., Lee, M., Hsu, P., Wang, C., Wei, Y., Liang, P., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00103s · Cited by 10
Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis
Puengel, T., & Tacke, F. (2024) · Liver International · doi:10.1111/liv.15783 · Cited by 7
Implications of liver fibrosis in clinical trials
Jahagirdar, V., Rama, K., Cabrera, D., Idalsoaga, F. J., Díaz, L. A., Arrese, M. A., & Arab, J. P. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102112 · Cited by 7
Lemmer, P., Rohr, L. C., Henning, M., Bulut, K., Manka, P. P., Canbay, A. E., & Sowa, J. (2024) · Digestive Diseases · doi:10.1159/000538426 · Cited by 6
“Since advanced fi brosis already has a relevant risk of progression, the term compensated advanced chronic liver disease, which comprises advanced fi brosis (F3) and cirrhosis (F4), was introduced [11, 12].”
BackgroundKawanaka, M., Nishino, K., Kawada, M., Ishii, K., Tanikawa, T., Urata, N., Suehiro, M., Haruma, K., & Kawamoto, H. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4373-24 · Cited by 7
Fujiwara, Y., Kuroda, H., Abe, T., Nagasawa, T., Nakaya, I., Ito, A., Watanabe, T., Yusa, K., Sato, H., Suzuki, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87974-w · Cited by 9
Alam, N., Ding, X., Fu, Y., Jia, L., Ali, S. M., & Liu, E. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2024 · Cited by 7
Liu, G., Mao, Q., Tian, X., Zhang, C., Zhang, Y., He, J., & Kong, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03955-3 · Cited by 8
“Individuals with NAFLD face an increased risk of premature mortality, not only due to liver-related causes but also from cardiovascular disease and extrahepatic cancers [5, 6].”
Hakim, A., Lin, K.-H., Schwantes-An, T.-H. L., Abreu, M., Tan, J., Guo, X., Yates, K. P., Lotta, L. A., Verweij, N., Loomba, R. S., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000728 · Cited by 6
“[20] We therefore utilized the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), one of the largest, multicenter, prospective cohorts of biopsy-confirmed fatty liver disease, including over 3000 participants, to evaluate previously identified MASLD genetic polymorphisms.”
Self-citationRole of imaging-guided biopsy for hepatocellular carcinoma
Cannella, R., Berman, Z. T., Tirukkovalur, N. V., Tohme, S. T., Minervini, M. I., & Furlan, A. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112271 · Cited by 7
Ren, Y., Chang, J. P. E., Tai, D., FILOZOF, C. M., Kleiner, D. E., & Sanyal, A. J. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.042 · Cited by 7
Self-citationHou, M., Zhu, Y., Zhou, H., Zhou, S., Zhang, J., Zhang, Y., & Liu, X. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01818-5 · Cited by 7
Putri, R. R. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1675713 · Cited by 8
Feng, Q., Manousou, P., Izzi‐Engbeaya, C. N., Loomba, R. S., Thursz, M. R., & Woodward, M. (2025) · Liver International · doi:10.1111/liv.70485 · Cited by 10
Self-citationBarrett, R., Archer, A. J., Cathcart, J., Abeysekera, K. W. M., Dillon, J. F., & Brennan, P. (2026) · Liver International · doi:10.1111/liv.70511 · Cited by 7
“Firstly, one study found there were a numerically increased number of HCC in F3 fibrosis than F4 fibrosis [33], but this represents relative differences in competing risk, especially for those with F4 disease, who are more likely to succumb to decompensated advanced chronic liver disease (dACLD).”
InfluentialBril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
“19,22,23 Large longitudinal studies show that as fibrosis advances from F1 to F4, the risk of liver-related morbidity rises exponentially, and fibrosis stage remains independently associated with all-cause mortality even after adjustment for metabolic comorbidities.”
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Kim, R. G., Chu, J. N., Vittinghoff, E., Deng, J., Reaso, J. N., Grenert, J. P., & Khalili, M. (2022) · Hepatology Communications · doi:10.1002/hep4.2078 · Cited by 6
“[32] Importantly, the presence of advanced fibrosis in FLD increases risk of liver- related complications and death.[33] However, few studies have explored FLD prevalence and risk factors among Asians in socioeconomically disadvantaged and vulnerable populations,[34] who are at risk of experiencing health disparities.”
BackgroundSeko, Y., Kawanaka, M., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Morishita, A., Munekage, K., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16019 · Cited by 6
Noninvasive Fibrosis Testing in Chronic Liver Disease Including Caveats
Buckholz, A. P., & Brown, R. S. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.008 · Cited by 7
Drozdov, I. A., Szubert, B., Rowe, I. A. C., Kendall, T. J., & Fallowfield, J. A. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101528 · Cited by 8
Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
Hoon, J., Park, N. R., Cho, S. W., Nam, H., Yang, H., Jung, E. S., Jang, J. W., Choi, J. Y., Yoon, S. K., Sung, P. S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444100 · Cited by 7
Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases
Deng, W.-Q., Ye, Z.-H., Tang, Z.-H., Zhang, X., & Lu, J. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.018 · Cited by 7
Bariatric Surgery and Risk of End-Stage Liver Disease in a Four-Country Cohort Study
Holmberg, D., Santoni, G., von Euler‐Chelpin, M., Kauppila, J. H., Ness‐Jensen, E., & Lagergren, J. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07857-x · Cited by 6
“MASLD and its subtype steatohepatitis are increasingly recognized as an important contributor to end-stage liver-disease [4, 5].”
Resolvin D1-mediated cellular crosstalk protects against MASH
Navarro‐Corcuera, A., Zhu, Y., Ma, F., Gupta, N., Asplund, H., Cogliati, B., Chipuk, J. E., Rom, O., Friedman, S. L., Sansbury, B. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101454 · Cited by 11
Canivet, C. M., Ongaro, M., Conquet, N., Spahr, L., & Goossens, N. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100747 · Cited by 7
Gries, J. J., Chen, B., Bansal, M. B., Rodríguez, M., Alqahtani, S. A., Brennan, P., Lang, C. C., Tang, W. H. W., Lazarus, J. V., & Krittanawong, C. (2025) · Communications Medicine · doi:10.1038/s43856-025-00951-2 · Cited by 8
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.11.001 · Cited by 10
Karsdal, M. A., Hallsworth, K., Scragg, J. H., Leeming, D. J., Villesen, I. F., Avery, L., Haigh, L., Govaere, O., Wichmann, S., Taylor, G., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000254 · Cited by 6
“Advanced NAFLD is associated with development of hepatic fibrosis, decreased liver function, and a high mortality rate due both to hepatic dysfunction and development of comorbidities related to cardiovascular disease, cancer, and kidney disease.[1,2] NAFLD is characterized by substantial interpatient variation in dis…”
BackgroundAlgorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting
Bech, K., Lindvig, K. P., Thiele, M. S., & Castéra, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0043-1778127 · Cited by 7
Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
Benlloch, S., Moncho, F., & Górriz, J. L. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.009 · Cited by 12
“The term NASH is therefore only one phase of MAFLD, namely the fatty inflammation phase (steatohepatitis) This phase implies a more accelerated progression of MAFLD, as it is where fibro-genic mechanisms are stimulated causing fibrosis at different stages, ultimately leading to cirrhosis The natural history of the diseas…”
BackgroundInfluentialSoni, A., Yekula, A., Singh, Y., Sood, N., Dahiya, D. S., Bansal, K., & Abraham, G. M. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i1.79 · Cited by 6
Lee, C.-H., Lui, D. T.-W., Li, R. H.-W., Yuen, M. M.-A., Fong, C. H.-Y., Leung, A. P.-W., Chu, J. C.-M., Mak, L. L.-Y., Lam, T.-H., Woo, J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1056562 · Cited by 5
“Early identification of individuals with clinically significant liver fibrosis, who are at risk of compensated advanced chronic liver disease (cACLD) (6, 7), is important to facilitate more targeted follow-up and surveillance, especially among overweight and obese individuals in whom the prevalence of MAFLD is over 50…”
BackgroundLee, H. A. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e65 · Cited by 7
“The stage of hepatic fibrosis in MASH is a critical determinant of clinical outcomes, as it can progress to cirrhosis and liver failure, and create conditions conducive to cancer development [54].”
de Jong, V., Alings, M., Brůha, R., Cortez‐Pinto, H., Dedoussis, G. V., Doukas, M., Francque, S., Fournier, C., Gastaldelli, A., Hankemeier, T., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092731 · Cited by 8
Wang, S., Xu, H., Du, R., Wei, C., Cui, X., Zhang, C., Zhong, M., Zhang, H., Wu, Q., Tong, G., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120192 · Cited by 6
Idalsoaga, F. J., Díaz, L. A., Alghsoon, S. A., Lawendy, B., Sharma, N., Desalegn, H., Yuan, Y., Ha, M. K., Le, J., MacDonald, J. K., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.035 · Cited by 7
Self-citationLi, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
“…multicenter study involving 1773 MASLD patients and found that only 0.04% person-years of patients with F0 – F2 fibrosis would progress into HCC. [30] Based on the present evidence, systematic screening for non-cirrhotic MASLD-HCC is far below the cost-effectiveness threshold and might not be…”
InfluentialKim, G., Jang, H., Kim, M. Y., Park, J. H., Park, J. G., Cho, E.-Y., Jeong, J. Y., Jeong, S., Han, S. K., 권희수, et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.007 · Cited by 15
Alamgir, M., Sohal, A., & Kowdley, K. V. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560039 · Cited by 6
“70 In an animal model, FGF-21 treatment was shown to inhibit osteoblastogenesis and stimulate adipogenesis in bone marrow, potentially leading to increased bone loss.”
Self-citationGee, M. F. W., Fonstad, R. K., Vol, E. B. D., Brown, C., Feld, J. J., Patel, K., & Sanyal, A. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000931 · Cited by 6
“[3,4] However, given the limited dynamic range of fibrosis stages, it can be challenging to identify which patient subpopulations are most likely to experience disease progression or regression.”
InfluentialSelf-citationGomes, M. B., Santos, D. C., Drummond, K. R. G., Pinheiro, A., Muniz, L. H., Leal, F. S. L., Negrato, C. A., Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), Melo, L. N., Cobas, R. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00996-0 · Cited by 5
Cordero, A., Escribano, D., Quintanilla, M. A., López-Ayala, J. M., Masiá, M. D., Cazorla, D., Rey-Rañal, E. M., Arribas, J. M., & Zuazola, P. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2022.12.008 · Cited by 5
Hydes, T., Cuthbertson, D. J., Palmer, D. H., Elshaarawy, O., Johnson, P. J., Fernando, R., & Cross, T. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2022.97 · Cited by 6
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting
Urias, E., & Chen, V. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2082-5203 · Cited by 6
Diagnostic et évaluation de l’hépatopathie stéatosique métabolique
Canivet, C. M., & Faure, S. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.10.438 · Cited by 5
Lee, J., Choi, S. M., Cho, S.-H., Yang, H., Sung, P. S., & Bae, S. H. (2024) · Diagnostics · doi:10.3390/diagnostics14040393 · Cited by 7
Park, H., Yoon, E. L., Kim, M., Kim, H., Kim, M. K., Kim, Y., & Jun, D. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-56085-3 · Cited by 5
“Indeed, the ’at-risk group’ not only faces a higher risk of liver disease but also experiences extrahepatic adverse outcomes, including cardiovascular diseases and malignancies 8–10 .”
BackgroundFlamm, S. L. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.05.015 · Cited by 10
The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients
Vogel, A. S., Roediger, R., Ahrens, D. V., Fortune, B. E., Schwartz, J. M., Frager, S. Z., Chacko, K. R., & Tow, C. (2024) · Life · doi:10.3390/life14060685 · Cited by 6
“Research has shown that those with MetALD have a higher risk for hepatic decompensation compared to their MASLD counterparts [56,57].”
BackgroundAlshoabi, S. A., Alharbi, R. M., Algohani, R. B., Al-Ahmadi, S., Ahmed, M., Faqeeh, S., Alahmadi, D., Qurashi, A. A., Alhazmi, F. H., Alrehaili, R. M., et al. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15030043 · Cited by 10
Lai, M., Lai, J. C., Allegretti, A. S., Patidar, K. R., & Cullaro, G. (2024) · Kidney360 · doi:10.34067/kid.0000000569 · Cited by 5
“24 We offer two hypotheses: ( 1 ) patients with increasing liver fi brosis have likely had SLD and its comorbidities for both a greater duration and a greater severity, thereby accumulating greater kidney damage over time, and ( 2 ) there may be pro fi brotic hepatic pathways that also have…”
InfluentialRole of artificial intelligence in staging and assessing of treatment response in MASH patients
Akpınar, R., Panzeri, D., Carlo, C. D., Belsito, V., Durante, B., Chirico, G. G., Lombardi, R., Fracanzani, A. L., Maggioni, M., Arcari, I., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1480866 · Cited by 6
Llamoza-Torres, C. J., Fuentes-Pardo, M., & Ramos‐Molina, B. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.64 · Cited by 12
Sapmaz, A., Paik, A., Henry, L. L., & Younossi, Z. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.70 · Cited by 10
Theel, W. B., de Jong, V., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14368 · Cited by 6
Noninvasive Grading of Liver Fibrosis Based on Texture Analysis From MRI‐Derived Radiomics
Gotta, J., Gruenewald, L. D., Reschke, P., Booz, C., Mahmoudi, S., Stieltjes, B., Choi, M. H., D’Angelo, T., Bernatz, S., Vogl, T. J., et al. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5301 · Cited by 7
Clark, V., Price, M. A., Russo, J., Loomba, R. S., Turner, A. M., & Strnad, P. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70009 · Cited by 7
“In clinical practice, the use of noninvasive tests (NITs) has largely replaced routine liver biopsy and provides an estimate of fibrosis stage [13, 14].”
Self-citationSubtypes of MASLD confer distinct clinical trajectories
Luukkonen, P. K. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.032 · Cited by 6
Association of NAFLD and Cardiovascular Events: A Systematic Review and Meta-analysis
Bhatia, M. K., Garg, A., Ali, J., Santos, A. D., Bhatia, M. K., Singh, B., Bassi, M., Broder, A., & Adler, D. G. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002232 · Cited by 7
Wang, Y., & Wan, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117423 · Cited by 7
Moore, J. A., Wheless, W. H., Zhang, J., Marsden, J. E., Mauldin, P. D., Moran, W. P., & Schreiner, A. D. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07959-5 · Cited by 8
Esteatosis hepática metabólica y nefropatía diabética: una llamada a la acción
Benlloch, S., Moncho, F., & Górriz, J. L. (2023) · Nefrología · doi:10.1016/j.nefro.2023.08.005 · Cited by 9
Schattenberg, J. M., Balp, M., Reinhart, B., Porwal, S., Tietz, A., Pedrosa, M. C., & Docherty, M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.004 · Cited by 5
Fukuda, T., Okamoto, T., Fukaishi, T., Kawakami, A., Tanaka, M., Yamada, T., & Monzen, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1392280 · Cited by 5
“Furthermore, NAFLD plays an important role in not only liver health but also metabolic abnormalities, including type 2 diabetes and cardiovascular disease, which, in turn, are associated with a high mortality rate (7).”
BackgroundSerum miR‑29 is increased in mice with early liver fibrosis
Matsumoto, K., Ohsugi, Y., Tayama, C., Hayashi, M., Kato, Y., Ohashi, M., & Chiba, M. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12573 · Cited by 6
“A liver biopsy is required to distinguish NASH, but the number of patients with suspected NASH is growing, and performing the procedure on all patients is difficult (5).”
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
Ko, D., Kim, D. H., Danpanichkul, P., Nakano, M., Rattananukrom, C., Wijarnpreecha, K., Ng, C. H., & Muthiah, M. D. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf037 · Cited by 6
“For example, in a prospective study of outcomes in adults with MASLD by Sanyal et al. [29], the end-organ complications only included new onsets of clinically obvious ascites, overt encephalopathy, or variceal hemorrhage.”
InfluentialIncidence and Predictors of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
Shalimar, S., Sheikh, S. S., Biswas, S., Vaishnav, M., Pathak, P., Pachisia, A. V., Narang, H., Prasad, S., Mehta, S., Dhooria, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.09.007 · Cited by 5
Cholankeril, G. T., & El‐Serag, H. B. (2022) · Seminars in Liver Disease · doi:10.1055/a-1957-8540 · Cited by 6
Chadha, N., Turner, A., & Sterling, R. K. (2022) · Journal of Viral Hepatitis · doi:10.1111/jvh.13763 · Cited by 5
A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Villota‐Rivas, M., Schattenberg, J. M., Wong, V. W., & Younossi, Z. M. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00603-7 · Cited by 6
Multi-Modality, Multi-Dimensional Characterization of Pediatric Non-Alcoholic Fatty Liver Disease
Jamshidi, N., Feizi, A., Sirlin, C. B., Lavine, J. E., & Kuo, M. (2023) · Metabolites · doi:10.3390/metabo13080929 · Cited by 5
“Although NAFLD is ultimately a disease of hepatic dysfunction, its development and progression are systemic, involving multiple organs [3].”
BackgroundOptimising the management of cardiovascular comorbidities in NAFLD patients: it’s time to (re-) act!
Kasper, P., Lang, S., Demir, M., & Steffen, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326662 · Cited by 6
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
Yilmaz, Y. N., & Kaya, E. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2022.2022.0044 · Cited by 11
“[4] According to current guidelines, this overarching goal should be achieved through a stepwise approach aimed at increasing the diagnostic and predictive certainty.”
BackgroundKalka, I. N., Hazzan, R., Yacovzada, N.-S., Igbaria, S., Segal, E., Weinberger, A., & Neeman, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-17534-9 · Cited by 4
Tong, X., Wan, Y., Yin, S., Shao, L., Yao, R., Ma, X., Rui, F., Shi, J., Wu, C., & Li, J. (2025) · Clinical Proteomics · doi:10.1186/s12014-024-09523-3 · Cited by 5
“NAFLD is intricately linked to obesity and includes a spectrum of conditions, including steatosis, non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even HCC [4, 5].”
IgA-enriched phenotype predicts liver-related events in MASLD
Kimura, T., Wakabayashi, S., Iwadare, T., Kondo, S., Okumura, T., Kobayashi, H., Yamashita, Y., Kamijo, Y., Fujita, K., Nakajima, T., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.06.044 · Cited by 6
Shiomi, A., Miyake, T., Furukawa, S., Matsuura, B., Yoshida, O., Watanabe, T., Kanamoto, A., Miyazaki, M., Nakaguchi, H., Tokumoto, Y., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14049 · Cited by 4
New Application of an Old Drug: Anti-Diabetic Properties of Phloroglucinol
Drygalski, K., Maciejczyk, M., Krasowska, U., Ustymowicz, A., Godzień, J., Buczyńska, A., Chomentowski, A., Walczak, I., Pietrowska, K., Siemińska, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910291 · Cited by 5
“This creates a vicious cycle, as excess body fat, especially visceral fat, further exacerbates insulin resistance, resulting in difficulty in losing weight or weight gain [6].”
BackgroundImpact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
Macías, J., Frías, M., Pineda, J. A., Corona‐Mata, D., Corma‐Gómez, A., Rivero‐Juárez, A., Santos, M. L., Deltoro, M. G., Rivero, A., Ricart-Olmos, C., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18413 · Cited by 4
“A recent study from the NASH Clinical Research Network based on liver biopsy, involving patients with NAFLD, reported that fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death [9].”
InfluentialDecharatanachart, P., Poovorawan, K., Tangkijvanich, P., Charatcharoenwitthaya, P., Peeraphatdit, T. B., Taychakhoonavudh, S., Treeprasertsuk, S., & Chaiteerakij, R. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003332 · Cited by 7
de Jong, V., Theel, W. B., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101337 · Cited by 6
Vargas, C. C., Cáceres, F., Landeira, G., Perez, S., Marchi, L., Ruffillo, G., Tevez, S., Puga‐Tejada, M., & Fassio, E. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002943 · Cited by 4
“[14] demonstrated a significant association between advanced liver fibrosis and an increase in the incidence of CVE, in disagreement with the findings of the NASH Clinical Research Network study [16].”
InfluentialThe Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
Henriksen, K., Chakravarthy, M. V., Bager, C. L., Larsen, A. T., Mohamed, K. E., & Karsdal, M. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16379 · Cited by 4
“53,56 Interestingly, in patients with MASH, the consequences of the disease often manifest in other organs, 40 underscoring the need to treat MASH and to do so as early as possible.”
Mia, M. A. R., Ahmed, Q. U., Ferdosh, S., Islam, M. S., Samdani, M. S., & Sarker, M. Z. I. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100814 · Cited by 4
Kim, M., Park, H., Yoon, E. L., Cheung, R. C., Kim, D., Kim, H., & Jun, D. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-01740-6 · Cited by 5
Katsarou, A., Papadopoulos, G., Moustakas, I. I., Papadopetraki, Α., Moustogiannis, A., Legaki, A., Giannousi, E., Agrogiannis, G. D., Pantelis, P., Veroutis, D., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156325 · Cited by 4
Bajaj, J. S., Reddy, K. R., Tandon, P., Lai, J. C., O’Leary, J. G., Wong, F. S.-H., García–Tsao, G., Vargas, H. E., Kamath, P. S., Biggins, S. W., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001462 · Cited by 5
Fittipaldi, J., Cardoso, S. W., Nunes, E. P., de Almeida, C. F., de Brito, P. D., Veloso, V. G., Grinsztejn, B. G. J., & Perazzo, H. (2025) · HIV Medicine · doi:10.1111/hiv.70079 · Cited by 4
“Similar results were observed in two multicentre prospective studies that followed large cohorts of people from the general population with biopsy-confirmed NAFLD [20, 21].”
Pan, L., Liu, J., Pang, G., Liu, G., & Tian, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s532630 · Cited by 4
López-Pascual, E., Moreno‐Torres, M., Moro, E., Rapisarda, A. S., Ortega-Vallbona, R., Serrano‐Candelas, E., Gozalbes, R., Jover, R., & Castell, J. V. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04178-x · Cited by 4
Multi-Omics Meets Premalignancy: Paving the Way for Early Prevention of Cancer
Zhang, F., Zhou, Z., Zhang, P., & Li, S. (2025) · Research · doi:10.34133/research.0930 · Cited by 6
Cheung, C. Y. Y., Wan, P., Wan, H., Xu, C., Jia, X., Fong, C. H.-Y., Lui, D. T. W., Song, E., Chen, X., Chow, W.-S., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.033 · Cited by 4
“Advanced liver fibrosis is considered as the most critical pathological change in MASLD [1], which is associated with liver-related complications and long-term mortality [3–5].”
Pirola, C. J., & Sookoian, S. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0960 · Cited by 8
Ananchaisarp, T., Chamroonkiadtikun, P., Bunchote, K., Thedpun, J., Srisamoot, C., Rujiworanat, C., Jayasakul, V., Chaiphom, N., Kittivarapong, T., Chuaysong, N., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03039-x · Cited by 4
“Advanced liver fibrosis, defined as fibrosis stage of at least F3, is significantly associated with an increased risk of liver-related complications in patients with MASLD [10, 11].”
Silvey, S. G., Patel, N., Davis, B., Sterling, R. K., Aljabi, A., Shenoy, A., Puri, P., Fuchs, M. A., BUSH, B. J., & Bajaj, J. S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003824 · Cited by 4
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Musso, G., Lassen, A., Banda, L., Maher, J. J., & Gambino, R. (2025) · BMJ · doi:10.1136/bmj-2025-084950 · Cited by 6
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.